DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for medulloblastoma — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMedulloblastoma maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for medulloblastoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) — PRKAR1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pcgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KJZ · 1.347 Å · ligand CYCLIC GUANOSINE MONOPHOSPHATE (PCG). Experimental structure, not a prediction.
What the evidence adds up to
A 1999 review notes that multi-modal therapy with radiation and chemotherapy had improved survival in medulloblastoma, but that treatment advances had occurred despite a poor understanding of the tumour’s biology. No specific survival numbers or response rates are given in that abstract.
A 2021 case report describes a 40-year-old man with recurrent medulloblastoma who received re-irradiation and six courses of bevacizumab, irinotecan, and temozolomide. He remained stable for six months. The authors state there is no effective therapy for adult medulloblastoma at initial appearance or recurrence, and call this regimen “promising” based on a single patient.
A 2025 case report describes a child with disseminated recurrent medulloblastoma treated with a modified metronomic and targeted antiangiogenesis regimen called MEMMAT, with LACE induction followed by autologous stem cell transplant as consolidation. The authors report complete remission in this single patient and claim metronomic therapy has high compliance and durable response, but provide no survival duration or sample size beyond the one case.
All three abstracts are based on reviews or single-patient reports. No randomised trial data are presented. What is missing is any prospective, controlled trial testing these drug combinations in a defined molecular subtype of medulloblastoma, adequate funding for such a trial, and patient stratification by age, recurrence pattern, and tumour biology.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Neurology · 1999 · 18 citations
Medulloblastoma
AbstractThe utilization of multi-modal therapy in the treatment of medulloblastoma has improved survival rates and overall outcome. Recent large clinical trials have supported the use of radiation and chemotherapy as adjuvant treatment. Treatment advances have been made despite a poor understanding of the biological underpinnings of medulloblastoma. Current laboratory investigations are shedding light on the oncogenesis of medulloblastoma and may lead to improved treatments.
Interdisciplinary Neurosurgery · 2021 · 2 citations · open access
Bevacizumab, irinotecan, and temozolomide with re-irradiation in adult recurrent medulloblastoma: A first case report
AbstractMedulloblastoma in adults is very rare, and there is no effective therapy for its initial appearance or recurrence. We present a case of a 40-year-old male with recurrent medulloblastoma despite initial radiochemotherapy. He received re-irradiation and 6 courses of bevacizumab, irinotecan, and temozolomide after which he remained stable for 6 months. This regimen may be promising for recurrent medulloblastoma in adults.
International Journal of Molecular and Immuno Oncology · 2025 · 0 citations · open access
Real life experience of complete remission with modified MEMMAT regimen with LACE induction followed by ASCT as consolidation in Recurrent Medulloblastoma -A case report
AbstractMedulloblastoma is a central nervous system tumor, it often recurs, and recurrence, if disseminated, is usually treated with high-dose chemotherapy of cyclophosphamide and etoposide. This therapy is replete with adverse effects, and compliance becomes a significant issue. Metronomic therapy is the safest way to treat malignancies in a very gentle manner. Compliance is very high, and response can be durable and deep. We present a real-life experience of using modified metronomic and targeted antiangiogenesis therapy for children with recurrent/progressive medulloblastoma, a regimen used in a case of a disseminated medulloblastoma patient.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
